JNJ-7706621
JNJ-7706621 is a dual-action small molecule inhibitor targeting aurora kinases as well as CDK1 and CDK2. It is utilized in cancer research to study cell cycle progression and mitotic events, demonstrating activity in both cellular assays and in vivo tumor models.
Product Specifications
CAS Number
443797-96-4
Product Name Alternative
Inhibit, JNJ 7706621, JNJ7706621, JNJ-7706621, Inhibitor, AuroraKinase, Aurora Kinase, Aurora A, Aurora B, Apoptosis, Cyclin dependent kinase, CDK2/CyclinA, CDK1/CyclinB, CDK, CDK2/CyclinE
Field of Research
Cell Biology, Epigenetics & Chromatin
Purity
99.10% (May vary between batches)
Solubility
DMSO:55 mg/mL (139.47 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.07 mM) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble)
Smiles
Nc1nc (Nc2ccc (cc2) S (N) (=O) =O) nn1C (=O) c1c (F) cccc1F
Molecular Formula
C15H12F2N6O3S
Molecular Weight
394.36
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog